Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Accelerated Phase Chronic Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Blast Phase Chronic Myeloid Leukemia
- Chronic Phase Chronic Myeloid Leukemia
- Leukemia
- Lymphoma
- Solid Tumors
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 1 years and 17 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03934372
- Collaborators
- Not Provided
- Investigators
- Study Director: Mohammed-El-Amine Bensmaine, MD Incyte Biosciences International Sàrl
Get Well Soon